RUSSIA/UKRAINE
As Russia’s clinical trial sector falls, Ukraine rebuilds
analyses the impact of the war on the clinical trial landscapes of Ukraine and Russia, as local investigators chronicle the situation on the ground.
I
Focusing on the clinical trials landscape, as
of August 2022, 28 foreign-sponsored, multi- country studies were publicly acknowledged by sponsors as being impacted by the war, according to GlobalData’s Clinical Trials Database. Of these, almost half had sites in both Ukraine and Russia. That said, the war’s ripple effects are likely to be far-reaching. Currently, the clinical trials sectors of both
countries appear to be on different paths. Ukrainian Association for Clinical Research president Dr Ivan Vyshnyvetskyy says Ukraine’s local activity is on the road to recovery. In fact, several studies are back to recruiting participants locally, and new studies have been initiating in the past several months, he adds. “At some point we started working like business as usual.” In Russia, it’s a different story. Dr Vladimir Andrianov recently left his position as director of the Department of Clinical Trials at the First Moscow State Medical University. Andrianov also left Russia.
Ukraine war froze clinical trial activity When the Ukraine war started, clinical trial activity in the country was frozen, Vyshnyvetskyy recollects. While some overseas-sponsored studies with recruited patients managed to continue, investigations with a small number of participants or ones that are yet to recruit
8 |
had local sites scrapped or put on hold, he adds. “Nobody knew what to do next because players did not know when the full-scale aggression would stop.” The war has impacted clinical trials in different
ways. Non-Ukraine trial sites in multinational studies may have had to recruit more participants to compensate for Ukraine sites closing, says research officer at CRO Biomapas, which has its headquarters in Lithuania. As another consequence, patients might
have been dropped from non-critical studies in order to prioritise the safety of Ukrainian trial would have been replaced by participants from sites in neighbouring countries. There is the option of adding more non-Ukraine sites and countries in the study, but it can be costly. GlobalData’s database shows that there
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44
